There are so many conflicting studies and concerns about hormone treatment in post-menopausal women. It gives relief to some, increases risks in others, and is a decision every woman and her doctor has to make on an individual basis -- What are the risks and benefits to me?
A new analysis from the Women's Health Initiative clinical trial presented at the 31st Annual San Antonio Breast Cancer Symposium discusses those risks, and shows that it's important to re-evaluation hormonal therapy from time to time. It says that stopping combined estrogen-plus-progestin hormone therapy in postmenopausal women who have a uterus helps their increased risk for breast cancer decline again.
"The risk goes away quickly," said researcher Roman Chlebowski, MD, PhD, from the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center in California. He said it takes about two years for a woman's risk to return to "baseline," or where she was before she began therapy.
Here's the complete story:
All user-generated information on this site is the opinion of its author only and is not a substitute for medical advice or treatment for any medical conditions. Members and guests are responsible for their own posts and the potential consequences of those posts detailed in our Terms of Service.